Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes

Medicine and Dentistry

• Cardiovascular System 100%
• Maturity Onset Diabetes of the Young 100%
• Congestive Heart Failure 66%
• Dipeptidyl Peptidase-4 Inhibitor 66%
• Glucagon-Like Peptide-1 Agonist 66%
• Sodium Glucose Cotransporter 2 Inhibitor 66%
• Kidney Function 33%
• Side Effect 33%
• Nephropathy 33%
• Glycon 33%
• Perioperative Period 33%
• Gastrointestinal Distress 33%
• Titrimetry 33%
• Diabetic Ketoacidosis 33%
• Saxagliptin 33%
• Alogliptin 33%
• Long Acting Drug 33%
• Short Acting Drug 33%
• Clinician 33%
• Blood Glucose 33%
• Sulfonylurea 33%
• Comorbidity 33%
• Diseases 33%
• Adverse Effect 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Dipeptidyl Peptidase IV Inhibitor 66%
• Coronary Artery Atherosclerosis 66%
• Congestive Heart Failure 66%
• Glucagon Like Peptide 1 Receptor Agonist 66%
• Sodium Glucose Cotransporter 2 Inhibitor 66%
• Sulfonylurea 33%
• Side Effect 33%
• Metformin 33%
• Gastrointestinal Symptom 33%
• Kidney Disease 33%
• Saxagliptin 33%
• Short Acting Drug 33%
• Long Acting Drug 33%
• Diabetic Ketoacidosis 33%
• Alogliptin 33%
• Comorbidity 33%
• Diseases 33%